Formulations for cathepsin k inhibitors

Abstract

The instant invention relates to pharmaceutical compositions containing cathepsin K inhibitors. Also disclosed are processes for making said pharmaceutical compositions.

What is claimed is: 
     
         1 . A pharmaceutical composition comprising from 1% to 95% by weight of an amorphous cathepsin K inhibitor system and from 5% to 99% by weight of excipients comprising a diluent, a glidant, a lubricant, a surfactant and a disintegrant. 
     
     
         2 . The pharmaceutical composition of  claim 1  comprising from 44% to 57% by weight of an amorphous cathepsin K inhibitor system and from 43% to 66% by weight of excipients comprising a diluent, a glidant, a lubricant, a surfactant and a disintegrant. 
     
     
         3 . The pharmaceutical composition of  claim 2  comprising 50.0% by weight of an amorphous cathepsin K inhibitor system and 50.0% by weight of excipients comprising a diluent, a glidant, a lubricant, a surfactant and a disintegrant. 
     
     
         4 . The pharmaceutical composition of  claim 1  wherein the amorphous cathepsin K inhibitor system comprises a cathepsin K inhibitor and a polymer. 
     
     
         5 . The pharmaceutical composition of  claim 4  wherein the cathepsin K inhibitor is N 1 -(1-cyanocyclopropyl)-4-fluoro-N 2 -{(1S)-2,2,2-trifluoro-1-[4′-(methylsulfonyl)-1,1′-biphenyl-4-yl]ethyl}-L-leucinamide, and the polymer is selected from the group consisting of HPMCAS-HF, HPMCAS-LF and Kollidon VA64. 
     
     
         6 . The pharmaceutical composition of  claim 5  wherein the polymer is HPMCAS-HF. 
     
     
         7 . The pharmaceutical composition of  claim 6  wherein the diluent is spray-dried lactose, the glidant is silicone dioxide, the lubricant is magnesium stearate, the surfactant is sodium laurel sulfate, and the disintegrant is croscarmellose sodium. 
     
     
         8 . A method of improving the absorption of a cathepsin K inhibitor by combining the cathepsin K inhibitor with a polymer to form an amorphous system. 
     
     
         9 . The method of  claim 8  wherein the cathepsin K inhibitor is N 1 -(1-cyanocyclopropyl)-4-fluoro-N 2 -{(1S)-2,2,2-trifluoro-1-[4′-(methylsulfonyl)-1,1′-biphenyl-4-yl]ethyl}-L-leucinamide, and the polymer is HPMCAS-HF.